Human Clinical Trials for Bimagrumab Lowered Body Fat Percentage in Patients

Steven Heymsfield, MD took his research into phase II of randomized clinical trials and have just published their results. Heymsfield and his colleagues at the Pennington Biomedical Research Center at Louisiana State University have been researching bimagrumab – a monoclonal antibody with the ability to block activin type II receptors. This process promotes skeletal growth and results showed a reduction in total body fat mass.

The trials involved adults with type 2 diabetes or obesity. In this trial, patients did not eat less than before and still experienced weight loss. The results were similar to those seen when patients with obesity took appetite suppressing medications to reduce food intake. The fact that the patients did not change eating habits but still had reduced body fat mass following the 48 week trial suggests that there might be a completely new mechanism at play. Now, Heymsfield has to evaluate the potential future paths his bimagrumab might take.

Are you developing new medicines? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts